Stem cells hidden in tumors may resist treatment
the ONA take:
Researchers are examining the functioning of cancer stem cells with regard to treatment resistance. Although the ability of stem cells to transform themselves into almost any kind of cell has great value in a variety of medical applications, the ability of cancer stem cells to adapt and resist cancer therapy is a new concern.
A mouse study conducted at Washington University School of Medicine has shown the presence of these stem cells not only in aggressive cancer but also in slower growing tumors as well.
The research team, led by senior author David H. Gutmann, MD, PhD, used a mouse model of neurofibromatosis type 1 low-grade brain tumors to examine cancer stem cells and to see if they had the capability to form tumors if transplanted into healthy mice without cancer.
The cancer stem cells could indeed form tumors in this manner. Cancer stem cells produce more copies of the protein Abcg1 than standard stem cells, which helps them survive stress.
The genetic disorder neurofibromatosis type 1(NF1) affects 1 in 2,500 babies and is responsible for a range of defects and disabilities, such as impaired vision, attention deficit hyperactivity disorder (ADHD), and heart and bone defects. Optic glioma is a brain tumor commonly seen in children with NF1.
This research determined that the drugs used to inhibit a cell growth pathway in optic glioma treatment are less effective versus the cancer stem cells, and the drug dosage may need to be increase as much as tenfold to compensate.
The study leaders feel that these cancer stem cells that have not yet developed into specialized cells represent a significant treatment obstacle that will require new strategies to overcome.
The ability of cancer stem cells to adapt and resist cancer therapy is a new concern.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|